论文部分内容阅读
目的观察沙丁胺醇联合布地奈德对咳嗽变异性哮喘疗效。方法纳入CVA患儿64例为观察对象,随机分为观察组和对照组各32例。两组均给予布地奈德气雾剂吸入,布地奈德2～7岁:200μg,2次/d;7岁以上:400μg,2次/d。咳嗽停止后续用至疗程满3个月改为200μg1次/d,维持3个月。同时,观察组给予沙丁胺醇气雾剂,每次1喷,3次/d。咳嗽消失后停药;对照组口服氯雷他定,体重>30kg:10mg,1次/d。体重≤30kg:5mg,1次/d。两组计入观察的疗程均为前3个月,峰流速仪测量最高呼气流速。结果①两组患者咳嗽消失率均为100%,观察组咳嗽消失时间为平均(9.75±4.90)d,对照组(13.83±6.19)d,两组比较有显著性差异(P<0.05);②治疗后两组PEF值均有显著增加(P<0.05),观察组晨、晚间PEF与观察组比较差异无显著性(P<0.05)。结论吸入型速效β2受体激动剂可快速有效缓解CVA患者咳嗽症状。
Objective To observe the curative effect of salbutamol combined with budesonide on cough variant asthma. Methods Sixty-four children with CVA were enrolled in the study. They were randomly divided into observation group (32 cases) and control group (32 cases). Both groups were given budesonide aerosol inhalation, budesonide 2 to 7 years old: 200μg, 2 times / d; 7 years old and above: 400μg, 2 times / d. Cough stop follow-up to the course of treatment for 3 months to 200μg1 times / d, for 3 months. At the same time, the observation group was given albuterol aerosol, 1 spray each time, 3 times / d. Cough disappeared after stopping; control group oral loratadine, body weight> 30kg: 10mg, 1 time / d. Weight ≤ 30kg: 5mg, 1 time / d. The two groups were included in the treatment of observation for the first 3 months, peak flow meter to measure the maximum expiratory flow rate. Results ① The disappearance rates of cough in both groups were all 100%. The disappearance time of cough in the observation group was 9.75 ± 4.90 days and 13.83 ± 6.19 days respectively, there was significant difference between the two groups (P <0.05). After treatment, the PEF values of both groups increased significantly (P <0.05). There was no significant difference between the observation group and the morning and evening PEF groups (P <0.05). Conclusion Inhaled fast-acting β2 receptor agonists can quickly and effectively relieve cough symptoms in CVA patients.